COMP <GO>
ANIK vs ABBV // FREE CASH FLOW YIELD
Anika Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ANIK 0
— ABBV 10
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $21.79 (+1.11%) • MKT CAP: $291.6M
fcf-yield
1.50%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIK VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIK | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.60% | 70.20% | -13.60 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | 29.00% | -39.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 1.50% | 3.47% | -1.97 | ABBV | /fcf-yield <GO> |
| Operating Margin | -9.80% | 24.60% | -34.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -9.80% | 6.90% | -16.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -5.90% | 8.60% | -14.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 65.1 | -11.96 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $291.6M | $513.86B | -$513.57B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIK REV | ABBV REV | ANIK GROSS % | ABBV GROSS % | ANIK FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $112.8M | $61.16B | 56.6% | 70.2% | $4.4M | $17.82B |
| FY 2024 | $119.9M | $56.33B | 63.4% | 70.0% | -$2.3M | $17.83B |
| FY 2023 | $120.8M | $54.32B | — | — | -$1.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIK // BETA —
ABBV // BETA 1.15